Javascript must be enabled to continue!
CHITOSAN COATED ROSUVASTATIN NANOSTRUCTURED LIPID CARRIERS: FORMULATION, IN VITRO CHARACTERIZATION AND STORAGE ASSESSMENTS
View through CrossRef
Background and Objective: Rosuvastatin calcium (ROS-Ca) is a synthetic, highly potent third-generation HMG-CoA reductase inhibitor with significant hypocholesterolemic effects. The objective of this study was to develop and characterize nanostructured lipid carriers (NLCs) as a delivery system for the poorly water-soluble drug rosuvastatin calcium (ROS-Ca), with the aim of enhancing its dissolution rate and improving oral bioavailability.
Methods: ROS-NLCs is prepared by hot homogenization–ultrasonication technique then the prepared formulations were further characterized. Finally compare their characteristics to the corresponding a positively charged chitosan coated to develop new CH-ROS-NLCs. In this study, glyceryl monostearate (GMS) was selected as solid lipids and Transcutol® HP as a liquid lipid, to develop ROS-NLC (nanostructured lipid carrier).
Results: The physicochemical properties were achieved. The prepared ROS-NLC formulation was showed in nanometric size (121.6±6.2 nm) with encapsulation efficiency (63±0.2%). Furthermore, ROS-NLC and CH-ROS-NLC appeared almost spherical nanoparticles in morphology under transmission electron microscope (TEM). DSC, XRD and FT-IR analysis showed that ROS was miscible, compatible, and incorporated into NLCs in amorphous form not in native crystalline state.
Conclusion: The previously results showed that ROS-Ca was successfully encapsulated into nanostructured lipid carriers (NLCs) which coated with chitosan CH-ROS-NLC to overcome the above-mentioned defects and, it was ensured that nanostructured lipid carriers have high beneficial effect for enhancing and improving the oral bioavailability of poorly water-soluble drugs such as Rosuvastatin.
Peer Review History:
Received 9 April 2025; Reviewed 12 May 2025; Accepted 22 June; Available online 15 July 2025
Academic Editor: Dr. DANIYAN Oluwatoyin Michael, Obafemi Awolowo University, ILE-IFE, Nigeria, toyinpharm@gmail.com
Reviewers:
Dr. Areen Alshweiat, University of Szeged, Hungary, areen.alshweiat@hu.edu.jo
Dr. Awofisayo, O Abosede, University of Uyo, Nigeria, shalomgirl08@yahoo.com
Society of Pharmaceutical Tecnocrats
Title: CHITOSAN COATED ROSUVASTATIN NANOSTRUCTURED LIPID CARRIERS: FORMULATION, IN VITRO CHARACTERIZATION AND STORAGE ASSESSMENTS
Description:
Background and Objective: Rosuvastatin calcium (ROS-Ca) is a synthetic, highly potent third-generation HMG-CoA reductase inhibitor with significant hypocholesterolemic effects.
The objective of this study was to develop and characterize nanostructured lipid carriers (NLCs) as a delivery system for the poorly water-soluble drug rosuvastatin calcium (ROS-Ca), with the aim of enhancing its dissolution rate and improving oral bioavailability.
Methods: ROS-NLCs is prepared by hot homogenization–ultrasonication technique then the prepared formulations were further characterized.
Finally compare their characteristics to the corresponding a positively charged chitosan coated to develop new CH-ROS-NLCs.
In this study, glyceryl monostearate (GMS) was selected as solid lipids and Transcutol® HP as a liquid lipid, to develop ROS-NLC (nanostructured lipid carrier).
Results: The physicochemical properties were achieved.
The prepared ROS-NLC formulation was showed in nanometric size (121.
6±6.
2 nm) with encapsulation efficiency (63±0.
2%).
Furthermore, ROS-NLC and CH-ROS-NLC appeared almost spherical nanoparticles in morphology under transmission electron microscope (TEM).
DSC, XRD and FT-IR analysis showed that ROS was miscible, compatible, and incorporated into NLCs in amorphous form not in native crystalline state.
Conclusion: The previously results showed that ROS-Ca was successfully encapsulated into nanostructured lipid carriers (NLCs) which coated with chitosan CH-ROS-NLC to overcome the above-mentioned defects and, it was ensured that nanostructured lipid carriers have high beneficial effect for enhancing and improving the oral bioavailability of poorly water-soluble drugs such as Rosuvastatin.
Peer Review History:
Received 9 April 2025; Reviewed 12 May 2025; Accepted 22 June; Available online 15 July 2025
Academic Editor: Dr.
DANIYAN Oluwatoyin Michael, Obafemi Awolowo University, ILE-IFE, Nigeria, toyinpharm@gmail.
com
Reviewers:
Dr.
Areen Alshweiat, University of Szeged, Hungary, areen.
alshweiat@hu.
edu.
jo
Dr.
Awofisayo, O Abosede, University of Uyo, Nigeria, shalomgirl08@yahoo.
com.
Related Results
Synthesis and Investigation into Apatite-forming Ability of Hydroxyapatite/Chitosan-based Scaffold
Synthesis and Investigation into Apatite-forming Ability of Hydroxyapatite/Chitosan-based Scaffold
In this study, porous scaffolds were fabricated using inorganic material-hydroxyapatite and chitosan for bone-tissue engineering. The combination of hydroxyapatite and chitosan may...
Nanostructured lipid carriers loaded with cannabidiol: A novel antibiofilm approach
Nanostructured lipid carriers loaded with cannabidiol: A novel antibiofilm approach
Introduction: Staphylococcus aureus and Staphylococcus epidermidis are major contributors to skin dysbiosis and infections, e.g. folliculitis and intravascular catheter infections,...
Rosuvastatin Alone or With Extended‐Release Niacin: A New Therapeutic Option for Patients With Combined Hyperlipidemia
Rosuvastatin Alone or With Extended‐Release Niacin: A New Therapeutic Option for Patients With Combined Hyperlipidemia
Combination therapy with a statin and niacin may provide optimal therapy for patients with combined hyperlipidemia and low levels of highdensity lipoprotein (HDL) cholesterol. The ...
Drought resistance and protein changes induced by chitosan in rice Oryza sativa L.
Drought resistance and protein changes induced by chitosan in rice Oryza sativa L.
This research aims to determine the appropriate chitosan types and concentrations for drought resistant induction in rice based on the hypothesized that the antioxidant system shou...
Structural and In-Vitro Characterization of Highly Swellable Β-Cyclodextrin Polymeric Nanogels Fabricated by Free Radical Polymerization for Solubility Enhancement of Rosuvastatin
Structural and In-Vitro Characterization of Highly Swellable Β-Cyclodextrin Polymeric Nanogels Fabricated by Free Radical Polymerization for Solubility Enhancement of Rosuvastatin
Basic aim of the study was to potentiate solubility of Rosuvastatin by loading it in synthesized nanogels. A set of nine different formulations was fabricated by an optimized free ...
Potable Water Sources, Household Hygiene, and Sanitation Practices in Ikpoba Okha LGA, Edo State: Implications for Public Health and Sustainable Water Management
Omoregie, Andrew Edosa.1 Omoregie Abieyuwa Peace2 Okoro, Enyinnaya Okoro.3
1 College of Medi
Potable Water Sources, Household Hygiene, and Sanitation Practices in Ikpoba Okha LGA, Edo State: Implications for Public Health and Sustainable Water Management
Omoregie, Andrew Edosa.1 Omoregie Abieyuwa Peace2 Okoro, Enyinnaya Okoro.3
1 College of Medi
BACKGROUND
Access to potable drinking water and sufficient sanitation continues to be an urgent global concern, particularly in developing regions where con...
Comparison Between Atorvastatin and Rosuvastatin on Anti- Thrombogenic Effect in Patients with Hyperlipidemia
Comparison Between Atorvastatin and Rosuvastatin on Anti- Thrombogenic Effect in Patients with Hyperlipidemia
Background: Atorvastatin and rosuvastatin are two widely used HMG-CoA reductase inhibitors (statins). These are used as lipid-lowering drugs to reduce atherosclerosis-induced cardi...
Is rosuvastatin protective against sepsis associated encephalopathy? A secondary analysis of the SAILS trial
Is rosuvastatin protective against sepsis associated encephalopathy? A secondary analysis of the SAILS trial
Abstract
Background
Sepsis is a common cause of death in emergency departments and sepsis associated encephalopathy is a major complication of sepsis. Rosuvastatin may hav...

